225Ac-DOTA-girentuximab

N/A

Report date: 2025/10/23 11:36:51

Base Information

Drug Name225Ac-DOTA-girentuximab
Drug Alias Name225Ac-DOTA-hG250225Ac-girentuximab225Ac-DOTA-G250
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugateRadiation-emitting products > Nuclides > Actinium > 225Ac +[4] 
Mechanisms of ActionCarbonic anhydrase IX modulators
TargetsCarbonic anhydrase IX
Therapy Area/IndicationsCarcinoma, Renal Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlandsAustralia and New Zealand
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesDepartment Of Clinical Pharmacy, University Medical Centre St Radboud, The Netherlands.
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTelix Pharmaceuticals LtdDepartment Of Clinical Pharmacy, University Medical Centre St Radboud, The Netherlands.
Active IndicationsN/A
Inactive IndicationsCarcinoma, Renal Cell

Other Information

ATC CodeN/A
Related LinksN/A